Sustained Increase in the Oral Bioavailability of Loperamide after a Single Oral Dose of HM30181, a P-glycoprotein Inhibitor, in Healthy Male Participants

Tolerability and Pharmacokinetics of a New P-Glycoprotein Inhibitor, HM30181, in Healthy Korean Male Volunteers: Single- and Multiple-Dose Randomized, Placebo-Controlled Studies

(2012) Tae-Eun Kim et al.   CLINICAL THERAPEUTICS

Simultaneous LC–MS–MS Determination of HM30181A, [2-(2-{4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]amide, as a new P-Glycoprotein Inhibitor and Its Two Metabolites, M1 and M2, in Human Plasma: Application to a Pharmacokinetic Study

(2011) Young Hee Choi et al.   CHROMATOGRAPHIA

P-glycoprotein Inhibition: The Past, the Present and the Future

(2011) Richard A.J. Darby et al.   CURRENT DRUG METABOLISM

Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges

(2010) Satyen J. Torne et al.   DRUG DELIVERY

N-desmethyl-Loperamide Is Selective for P-Glycoprotein among Three ATP-Binding Cassette Transporters at the Blood-Brain Barrier

(2010) P. Kannan et al.   DRUG METABOLISM AND DISPOSITION

Uptake/Efflux Transport of Tramadol Enantiomers andO-Desmethyl-Tramadol: Focus onP-Glycoprotein

(2009) Mouna Kanaan et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel

(2009) Jin-Oh Kwak et al.   EUROPEAN JOURNAL OF PHARMACOLOGY